In metastatic HR+ HER2-negative breast cancer, previous studies have identified several prognostic indicators, including higher HER2 immunohistochemistry scores, estrogen receptor (ER) expression levels, Ki67 index, poor differentiation, and the presence of an objective response [27,28,29,30,31,32]. The gene discussed is ESR1; the disease is breast carcinoma.